GALT Stock Price - Galectin Therapeutics Inc. logo

GALT Stock Price

Galectin Therapeutics Inc.

$2.91
-$0.11(-3.64%)
25
Overall
40
Value
10
Tech
26
Quality
How is this score calculated?
Market Cap
$293.47M
Volume
262.80K
52W Range
$2.03 - $7.13
Target Price
$11.00

GALT stock price is $2.91 (-3.64% on the day), giving Galectin Therapeutics Inc. a market cap of $293.47M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.

GALT Stock Overview

Price
$2.91
Previous close
$3.02
Open
$3.11
Market cap
$293.47M
52-week range
$2.02 - $7.13
1-year price target
$11.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
Nasdaq
MarketXLS Rank
25

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

ABCD
1SymbolPriceChangeVol
2GALT$2.91-3.6%262.80K
3
4
5
6

Get Galectin Therapeutics Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.